| Filed On | Filing |
|---|---|
| 13 Nov 2026 | QUARTERLY REPORT |
| 13 Nov 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 11 Aug 2026 | QUARTERLY REPORT |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
BOCA RATON, Fla.--(BUSINESS WIRE)—August 11, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months e... |
| 05 Aug 2026 | SCHEDULE 13G/A |
| 12 May 2026 | QUARTERLY REPORT |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
BOCA RATON, Fla.--(BUSINESS WIRE)—May 12, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ende... |
| 06 Apr 2026 | SCHEDULE 13G |
| 01 Apr 2026 | ANNUAL REPORT |
| 01 Apr 2026 | NOTIFICATION OF LATE FILING |
| 30 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
BOCA RATON, Fla.--(BUSINESS WIRE)—March 30, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended... |
| 30 Mar 2026 | ANNUAL REPORT |
| 21 Jan 2026 |
8-K: Changes in Registrant's Certifying Accountant
We are the former independent registered public accounting firm for TherapeuticsMD, Inc. (the “Company”). |
| 29 Dec 2025 |
Form 4: Thompson Tommy G, Director
Bought 8,400 shares ($14K) |
| 16 Dec 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On December 15, 2025, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), held its 2025 Annual Meeting (the “Annual Meeting”). At the close of business on October 20, 2025, the record date for the determination of stockholders en... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
BOCA RATON, Fla.--(BUSINESS WIRE)—November 12, 2025 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months... |
| 12 Nov 2025 | QUARTERLY REPORT |
| 05 Nov 2025 |
Form 4: Thompson Tommy G, Director
Granted 8,500 Restricted Stock Units |
| 05 Nov 2025 |
Form 4: Naughton Gail K, Director
Granted 8,500 Restricted Stock Units |
| 05 Nov 2025 |
Form 4: Collins Cooper C., Director
Granted 8,500 Restricted Stock Units |
Loading...